title: Application of serum NY-ESO-1 antibody assay for early SCLC diagnosis.
abstract: BACKGROUND
  NY-ESO-1 antibody is one of the cancer-related antibodies. The purpose of this study was to investigate the diagnostic role of the NY-ESO-1 humoral immune response in small cell lung cancer (SCLC).
  
  
  METHODS
  We recombined the recombinant protein of NY-ESO-1 antibody and NSE, analyzed them by Enzyme-linked immunosorbent assay, and then established the Receiver Operating Characteristic (ROC) curve to estimate the diagnostic value of NY-ESO-1 antibody, NSE and their combinations.
  
  
  RESULTS
  According to detection, the positive rate of NY-ESO-1 humoral immune response (26.3%), NSE (43.8%) and their combinations (10.5%) were all lower than the negative rate which indicated that the NY-ESO-1 antibody might be down-regulated in SCLC. And the positive rate wasn't related to clinicopathologic characteristics. The ROC curve demonstrated that with a 37.17% sensitivity and a 91.7% specificity along with a AUC of 0.619 for NY-ESO-1ab as well as with a 48.3% sensitivity and a 90.87% specificity along with a AUC value of 0.773 for NSE, their diagnostic value were both high. Besides, the diagnostic value of their combinations was also good for a AUC of 0.83 and a 69.12% sensitivity and a 91.8% specificity. There were significant difference of diagnostic value among three types above (NY-ESO-1 vs. NSE, P < 0.01; The Combinations vs. NY-ESO-1, P < 0.0001; and the Combinations vs. NSE, P < 0.04).
  
  
  CONCLUSIONS
  In conclusion, NY-ESO-1ab, NSE and their combinations all were important diagnostic markers for SCLC. Moreover, the diagnostic value of their combinations was higher than any single of them. And NY-ESO-1 humoral immune to NSE might be a potential diagnostic indicator in SCLC.
authors.affiliation: Center of Tumor Therapy, Navy General Hospital Beijing 100048, China.
authors.forename: Jihua
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Medical Oncology, Chinese People's Liberation Army General Hospital Beijing 100853, China.
authors.forename: Shunchang
authors.initials: S
authors.lastname: Jiao
authors.affiliation: Center of Tumor Therapy, Navy General Hospital Beijing 100048, China.
authors.forename: Jingbo
authors.initials: J
authors.lastname: Kang
authors.affiliation: Second Military Medical University Shanghai 200433, China.
authors.forename: Rong
authors.initials: R
authors.lastname: Li
authors.affiliation: Department of Medical Oncology, General Hospital of Shenyang Military Command Shenyang, Liaoning Province, China.
authors.forename: Guanzhong
authors.initials: G
authors.lastname: Zhang
mesh_terms: D000368:Aged; D000951:Antigens, Neoplasm / Q000097:blood*; D019540:Area Under Curve; D001323:Autoantibodies / Q000097:blood*; D001324:Autoantigens / Q000276:immunology; D014408:Biomarkers, Tumor / Q000097:blood*; D055088:Early Detection of Cancer / Q000379:methods*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D056724:Immunity, Humoral; D008175:Lung Neoplasms / Q000097:blood / Q000175:diagnosis*; D008297:Male; D008565:Membrane Proteins / Q000097:blood*; D008875:Middle Aged; D012372:ROC Curve; D011994:Recombinant Proteins / Q000276:immunology; D012680:Sensitivity and Specificity; D055752:Small Cell Lung Carcinoma / Q000097:blood / Q000175:diagnosis*
chemical_list: D000951:Antigens, Neoplasm; D001323:Autoantibodies; D001324:Autoantigens; D014408:Biomarkers, Tumor; C104948:CTAG1B protein, human; D008565:Membrane Proteins; D011994:Recombinant Proteins
keywords: NY-ESO-1; SCLC; diagnosis
references.citation: J Exp Med. 1998 Apr 20;187(8):1349-54
references.pmid: 9547346
references.citation: Autoimmun Rev. 2003 May;2(3):119-25
references.pmid: 12848952
references.citation: Ann Oncol. 2011 Feb;22(2):383-9
references.pmid: 20675559
references.citation: Tunis Med. 2011 Oct;89(10):779-83
references.pmid: 22076902
references.citation: Oncoimmunology. 2012 Nov 1;1(8):1409-1410
references.pmid: 23243610
references.citation: Mech Ageing Dev. 1995 Mar 1;78(2):145-54
references.pmid: 7596195
references.citation: J Thorac Oncol. 2006 Jul;1(6):513-9
references.pmid: 17409910
references.citation: J Cardiothorac Surg. 2009;4:30
references.pmid: 19589150
references.citation: Clin Exp Immunol. 1987 Sep;69(3):557-65
references.pmid: 3499270
references.citation: J Thorac Cardiovasc Surg. 2005 Jan;129(1):64-72
references.pmid: 15632826
references.citation: Ann Oncol. 2010 Aug;21(8):1687-93
references.pmid: 20124350
references.citation: Ann Oncol. 2007 May;18(5):868-73
references.pmid: 17347129
references.citation: PLoS One. 2011;6(6):e21129
references.pmid: 21747904
references.citation: Br J Cancer. 2013 Mar 19;108(5):1119-25
references.pmid: 23403818
references.citation: Cancer. 2000 Aug 1;89(3):523-33
references.pmid: 10931451
references.citation: Cancer Immun. 2003 Jul 31;3:10
references.pmid: 12889868
references.citation: Thorax. 2008 Mar;63(3):228-33
references.pmid: 17932110
references.citation: Mech Ageing Dev. 1997 Mar;94(1-3):183-90
references.pmid: 9147370
references.citation: Clin Cancer Res. 2011 Mar 15;17(6):1474-80
references.pmid: 21138858
references.citation: J Clin Oncol. 2008 Nov 1;26(31):5060-6
references.pmid: 18794547
references.citation: Ann Thorac Med. 2015 Jan-Mar;10(1):61-6
references.pmid: 25593610
references.citation: Chest. 2003 Jan;123(1 Suppl):259S-271S
references.pmid: 12527584
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43
references.pmid: 12582023
references.citation: Adv Cancer Res. 2006;95:1-30
references.pmid: 16860654
references.citation: Cancer Lett. 2006 May 8;236(1):64-71
references.pmid: 15992994